Antonio Valentim Goncalves
Overview
Explore the profile of Antonio Valentim Goncalves including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
65
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Valentim Goncalves A
Rev Port Cardiol
. 2024 Aug;
43(12):695-697.
PMID: 39216532
No abstract available.
2.
Barbas de Albuquerque F, Teixeira R, Pereira-da-Silva T, Ferreira V, Valentim Goncalves A, Moreira R, et al.
Rev Port Cardiol
. 2024 Aug;
44(1):1-8.
PMID: 39216531
Introduction And Objectives: Left ventricular global longitudinal strain (LVGLS) is an indicator of myocardial function in patients with heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF)....
3.
Garcia Bras P, Valentim Goncalves A, Reis J, Moreira R, Pereira-da-Silva T, Rio P, et al.
Life (Basel)
. 2023 Oct;
13(10).
PMID: 37895367
Background: Exercise testing is key in the risk stratification of patients with heart failure (HF). There are scarce data on its prognostic power in women. Our aim was to assess...
4.
Garcia Bras P, Valentim Goncalves A, Reis J, Moreira R, Pereira-da-Silva T, Rio P, et al.
Medicina (Kaunas)
. 2023 Sep;
59(9).
PMID: 37763804
: Cardiopulmonary exercise testing (CPET) is a cornerstone of risk stratification in heart failure with reduced ejection fraction (HFrEF). However, there is a paucity of evidence on its predictive power...
5.
Garcia Bras P, Valentim Goncalves A, Reis J, Moreira R, Pereira-da-Silva T, Rio P, et al.
Biomedicines
. 2023 Aug;
11(8).
PMID: 37626705
Background: New therapies with prognostic benefits have been recently introduced in heart failure with reduced ejection fraction (HFrEF) management. The aim of this study was to evaluate the prognostic power...
6.
Garcia Bras P, Valentim Goncalves A, Moura Branco L, Moreira R, Pereira-da-Silva T, Galrinho A, et al.
Life (Basel)
. 2023 Apr;
13(4).
PMID: 37109524
Background: Data on the impact of sacubitril/valsartan (SV) therapy on phasic left atrial (LA) and left ventricular (LV) strain in heart failure with reduced ejection fraction (HFrEF) are limited. The...
7.
Garcia Bras P, Rosa S, Cardoso I, Moura Branco L, Galrinho A, Valentim Goncalves A, et al.
J Am Heart Assoc
. 2023 Apr;
12(8):e028857.
PMID: 37066817
Background Two-dimensional speckle tracking echocardiography has been shown to correlate with microvascular dysfunction, a hallmark of hypertrophic cardiomyopathy (HCM). We hypothesized that there is an association between myocardial work and...
8.
Valentim Goncalves A, Reis J, Timoteo A, Soares R, Pereira-da-Silva T, Gomes V, et al.
Arq Bras Cardiol
. 2023 Mar;
120(2):e20220205.
PMID: 36856238
No abstract available.
9.
Reis J, Valentim Goncalves A, Moreira R, Pereira da Silva T, Timoteo A, Pombo D, et al.
Rev Port Cardiol
. 2023 Jan;
42(4):335-343.
PMID: 36634758
Introduction: Patients with advanced heart failure (HF) have high morbidity and mortality, with only a small proportion being eligible for advanced therapies. Intermittent outpatient levosimendan infusion has been shown to...
10.
Reis J, Valentim Goncalves A, Garcia Bras P, Moreira R, Rio P, Timoteo A, et al.
Arq Bras Cardiol
. 2022 Jul;
119(3):413-423.
PMID: 35857944
Background: There is evidence suggesting that a peak oxygen uptake (pVO2) cut-off of 10ml/kg/min provides a more precise risk stratification in cardiac resynchronization therapy (CRT) patients. Objective: To compare the...